Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice

Jianping Wen, Nong Xu, Anna Li, Jacqueline Bourgeois, Frederick A. Ofosu, Gonzalo Hortelano

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Hemophilia B is a bleeding disorder caused by defective factor IX (FIX), currently treated by regular infusions of plasma-derived or recombinant FIX. We propose a gene therapy strategy based on the implantation of cells secreting FIX enclosed in alginate microcapsules as a highly desirable alternative treatment. We have reported sustained delivery of human factor IX (hFIX) in immunocompetent mice implanted with encapsulated primary mouse myoblasts engineered to secrete hFIX. As a step towards the treatment of human patients, in this study we report the implantation of encapsulated human primary myoblasts secreting hFIX in hemophilia B mice. Methods: Human primary myoblasts were transfected with plasmids pKL4M-hFIX, pLNM-βIXL, pMFG-hFIX, and transduced with retrovirus MFG-hFIX. Two human primary myoblast clones secreting ∼1 μg hFIX/106 cells/day were enclosed in biocompatible alginate microcapsules and implanted intraperitoneally into SCID and hemophilic mice. Results: Circulating hFIX (peak of ∼120 ng/ml) was detected in hemophilia B mice on day 1 after implantation. Human FIX delivery was transient, however, becoming undetectable on day 14. Concurrently, anti-hFIX antibodies were detected. At the same time, activated partial thromboplastin time (APTT) was reduced from 94 s before treatment to 78-80 s. Tail bleeding time decreased from 15 min to 1.5-7 min after treatment, some mice being normalised. These findings indicate that the delivered hFIX is biologically active. Similarly treated NOD/SCID mice had circulating hFIX levels of 170 ng/ml on day 1 that remained detectable for 1 month, albeit at low levels. Cell viability of microcapsules retrieved on day 60 was below 5%. Conclusions: Our findings indicate that encapsulated human primary myoblasts secrete functional hFIX. Furthermore, implantation of encapsulated human primary myoblasts can partially correct the phenotype of hemophilia B mice, supporting the feasibility of this gene therapy approach for hemophilia B. However, the long-term viability of the encapsulated human myoblasts must first be improved.

Original languageEnglish
Pages (from-to)1002-1010
Number of pages9
JournalJournal of Gene Medicine
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 2007
Externally publishedYes

Fingerprint

Factor IX
Myoblasts
Hemophilia B
Capsules
SCID Mice
Genetic Therapy
Inbred NOD Mouse

Keywords

  • Alginate
  • Factor IX
  • Gene therapy
  • Hemophilia B
  • Microcapsules
  • Myoblasts

ASJC Scopus subject areas

  • Genetics

Cite this

Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice. / Wen, Jianping; Xu, Nong; Li, Anna; Bourgeois, Jacqueline; Ofosu, Frederick A.; Hortelano, Gonzalo.

In: Journal of Gene Medicine, Vol. 9, No. 11, 11.2007, p. 1002-1010.

Research output: Contribution to journalArticle

Wen, Jianping ; Xu, Nong ; Li, Anna ; Bourgeois, Jacqueline ; Ofosu, Frederick A. ; Hortelano, Gonzalo. / Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice. In: Journal of Gene Medicine. 2007 ; Vol. 9, No. 11. pp. 1002-1010.
@article{1357084881e14b099159b7cace9de544,
title = "Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice",
abstract = "Background: Hemophilia B is a bleeding disorder caused by defective factor IX (FIX), currently treated by regular infusions of plasma-derived or recombinant FIX. We propose a gene therapy strategy based on the implantation of cells secreting FIX enclosed in alginate microcapsules as a highly desirable alternative treatment. We have reported sustained delivery of human factor IX (hFIX) in immunocompetent mice implanted with encapsulated primary mouse myoblasts engineered to secrete hFIX. As a step towards the treatment of human patients, in this study we report the implantation of encapsulated human primary myoblasts secreting hFIX in hemophilia B mice. Methods: Human primary myoblasts were transfected with plasmids pKL4M-hFIX, pLNM-βIXL, pMFG-hFIX, and transduced with retrovirus MFG-hFIX. Two human primary myoblast clones secreting ∼1 μg hFIX/106 cells/day were enclosed in biocompatible alginate microcapsules and implanted intraperitoneally into SCID and hemophilic mice. Results: Circulating hFIX (peak of ∼120 ng/ml) was detected in hemophilia B mice on day 1 after implantation. Human FIX delivery was transient, however, becoming undetectable on day 14. Concurrently, anti-hFIX antibodies were detected. At the same time, activated partial thromboplastin time (APTT) was reduced from 94 s before treatment to 78-80 s. Tail bleeding time decreased from 15 min to 1.5-7 min after treatment, some mice being normalised. These findings indicate that the delivered hFIX is biologically active. Similarly treated NOD/SCID mice had circulating hFIX levels of 170 ng/ml on day 1 that remained detectable for 1 month, albeit at low levels. Cell viability of microcapsules retrieved on day 60 was below 5{\%}. Conclusions: Our findings indicate that encapsulated human primary myoblasts secrete functional hFIX. Furthermore, implantation of encapsulated human primary myoblasts can partially correct the phenotype of hemophilia B mice, supporting the feasibility of this gene therapy approach for hemophilia B. However, the long-term viability of the encapsulated human myoblasts must first be improved.",
keywords = "Alginate, Factor IX, Gene therapy, Hemophilia B, Microcapsules, Myoblasts",
author = "Jianping Wen and Nong Xu and Anna Li and Jacqueline Bourgeois and Ofosu, {Frederick A.} and Gonzalo Hortelano",
year = "2007",
month = "11",
doi = "10.1002/jgm.1098",
language = "English",
volume = "9",
pages = "1002--1010",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice

AU - Wen, Jianping

AU - Xu, Nong

AU - Li, Anna

AU - Bourgeois, Jacqueline

AU - Ofosu, Frederick A.

AU - Hortelano, Gonzalo

PY - 2007/11

Y1 - 2007/11

N2 - Background: Hemophilia B is a bleeding disorder caused by defective factor IX (FIX), currently treated by regular infusions of plasma-derived or recombinant FIX. We propose a gene therapy strategy based on the implantation of cells secreting FIX enclosed in alginate microcapsules as a highly desirable alternative treatment. We have reported sustained delivery of human factor IX (hFIX) in immunocompetent mice implanted with encapsulated primary mouse myoblasts engineered to secrete hFIX. As a step towards the treatment of human patients, in this study we report the implantation of encapsulated human primary myoblasts secreting hFIX in hemophilia B mice. Methods: Human primary myoblasts were transfected with plasmids pKL4M-hFIX, pLNM-βIXL, pMFG-hFIX, and transduced with retrovirus MFG-hFIX. Two human primary myoblast clones secreting ∼1 μg hFIX/106 cells/day were enclosed in biocompatible alginate microcapsules and implanted intraperitoneally into SCID and hemophilic mice. Results: Circulating hFIX (peak of ∼120 ng/ml) was detected in hemophilia B mice on day 1 after implantation. Human FIX delivery was transient, however, becoming undetectable on day 14. Concurrently, anti-hFIX antibodies were detected. At the same time, activated partial thromboplastin time (APTT) was reduced from 94 s before treatment to 78-80 s. Tail bleeding time decreased from 15 min to 1.5-7 min after treatment, some mice being normalised. These findings indicate that the delivered hFIX is biologically active. Similarly treated NOD/SCID mice had circulating hFIX levels of 170 ng/ml on day 1 that remained detectable for 1 month, albeit at low levels. Cell viability of microcapsules retrieved on day 60 was below 5%. Conclusions: Our findings indicate that encapsulated human primary myoblasts secrete functional hFIX. Furthermore, implantation of encapsulated human primary myoblasts can partially correct the phenotype of hemophilia B mice, supporting the feasibility of this gene therapy approach for hemophilia B. However, the long-term viability of the encapsulated human myoblasts must first be improved.

AB - Background: Hemophilia B is a bleeding disorder caused by defective factor IX (FIX), currently treated by regular infusions of plasma-derived or recombinant FIX. We propose a gene therapy strategy based on the implantation of cells secreting FIX enclosed in alginate microcapsules as a highly desirable alternative treatment. We have reported sustained delivery of human factor IX (hFIX) in immunocompetent mice implanted with encapsulated primary mouse myoblasts engineered to secrete hFIX. As a step towards the treatment of human patients, in this study we report the implantation of encapsulated human primary myoblasts secreting hFIX in hemophilia B mice. Methods: Human primary myoblasts were transfected with plasmids pKL4M-hFIX, pLNM-βIXL, pMFG-hFIX, and transduced with retrovirus MFG-hFIX. Two human primary myoblast clones secreting ∼1 μg hFIX/106 cells/day were enclosed in biocompatible alginate microcapsules and implanted intraperitoneally into SCID and hemophilic mice. Results: Circulating hFIX (peak of ∼120 ng/ml) was detected in hemophilia B mice on day 1 after implantation. Human FIX delivery was transient, however, becoming undetectable on day 14. Concurrently, anti-hFIX antibodies were detected. At the same time, activated partial thromboplastin time (APTT) was reduced from 94 s before treatment to 78-80 s. Tail bleeding time decreased from 15 min to 1.5-7 min after treatment, some mice being normalised. These findings indicate that the delivered hFIX is biologically active. Similarly treated NOD/SCID mice had circulating hFIX levels of 170 ng/ml on day 1 that remained detectable for 1 month, albeit at low levels. Cell viability of microcapsules retrieved on day 60 was below 5%. Conclusions: Our findings indicate that encapsulated human primary myoblasts secrete functional hFIX. Furthermore, implantation of encapsulated human primary myoblasts can partially correct the phenotype of hemophilia B mice, supporting the feasibility of this gene therapy approach for hemophilia B. However, the long-term viability of the encapsulated human myoblasts must first be improved.

KW - Alginate

KW - Factor IX

KW - Gene therapy

KW - Hemophilia B

KW - Microcapsules

KW - Myoblasts

UR - http://www.scopus.com/inward/record.url?scp=36148959328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148959328&partnerID=8YFLogxK

U2 - 10.1002/jgm.1098

DO - 10.1002/jgm.1098

M3 - Article

VL - 9

SP - 1002

EP - 1010

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 11

ER -